Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
1.240
-0.090 (-6.77%)
At close: Nov 20, 2026, 4:00 PM EST
1.249
+0.009 (0.71%)
After-hours: Nov 20, 2026, 7:34 PM EST
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $593.00K in the quarter ending September 30, 2026, with 68.95% growth. This brings the company's total for the last twelve months to $2.13M. In the year 2025, Seres Therapeutics had annual revenue of $789.00K. That makes Seres Therapeutics the 42,284th largest company in the world by revenue and 5,752nd in the United States.
Revenue (ttm)
$2.13M
Revenue Growth
+505.41%
P/S Ratio
5.95
Revenue / Employee
$32,197
Employees
66
Market Cap
12.64M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| BioStem Technologies | 31.75M |
| Bolt Biotherapeutics | 4.70M |
| BeyondSpring | 1.88M |
| Pluri | 1.46M |
| Neuphoria Therapeutics | 1.17M |
| Allarity Therapeutics | 350.00K |
| BioCardia | 3.00K |
MCRB News
- 18 days ago - Seres Therapeutics Reports Third Quarter 2026 Financial Results and Announces Plans for Advancing Development of SER-155 To Prevent Immune Checkpoint Inhibitor-Related Enterocolitis (irEC) - GlobeNewsWire
- 18 days ago - Seres Therapeutics Earnings release: Q3 2026 - Filings
- 18 days ago - Seres Therapeutics Quarterly report: Q3 2026 - Filings
- 19 days ago - Seres Therapeutics’ SER-155 cuts bloodstream infection risk 77% in study - TheFly
- 19 days ago - Seres Therapeutics Announces Publication of SER-155 Phase 1b Results in Nature Medicine Showing Reduced Bloodstream Infections in Allogeneic Hematopoietic Cell Transplantation Recipients - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 - GlobeNewsWire
- 2 months ago - Seres Therapeutics Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 2 months ago - Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire